ScienceDaily
Your source for the latest research news
Follow Facebook Twitter LinkedIn Subscribe RSS Feeds Newsletters
New:
  • Alligators Can Regrow Their Tails Too
  • Two Liquid States of Water Exist
  • Zebra Finches Unmask the Bird Behind the Song
  • Most Effective Strategies to Cut COVID-19 Spread
  • Memory 'Fingerprints' Reveal Brain Organization
  • A Biochemical Random Number
  • Geology at Mars' Equator: Ancient Megaflood
  • How the Brain Forms Sensory Memories
  • Healthy Sleep Habits Cut Risk of Heart Failure
  • NASA's SpaceX Crew-1 Astronauts Headed to ISS
advertisement
Follow all of ScienceDaily's latest research news and top science headlines!
Science News
from research organizations

1

2

Warning signs over effectiveness of HIV 'wonder drug' in sub-Saharan Africa

Date:
December 1, 2020
Source:
University of Cambridge
Summary:
Dolutegravir, the current first-line treatment for HIV, may not be as effective as hoped in sub-Saharan Africa, suggests new research published on World AIDS Day. The study finds that this so-called 'wonder drug' may be less effective in patients resistant to older drugs.
Share:
FULL STORY

Dolutegravir, the current first-line treatment for HIV, may not be as effective as hoped in sub-Saharan Africa, suggests new research published on World AIDS Day. The study finds that this so-called 'wonder drug' may be less effective in patients resistant to older drugs.

advertisement

As HIV copies itself and replicates, it can develop errors, or 'mutations', in its genetic code (its RNA). While a drug may initially be able to supress or even kill the virus, certain mutations can allow the virus to develop resistance to its effects. If a mutated strain begins to spread within a population, it can mean once-effective drugs are no longer able to treat people.

HIV treatment usually consists of a cocktail of drugs that includes a type of drug known as a non-nucleoside reverse-transcriptase inhibitor (NNRTI). However, in recent years, HIV has begun to develop resistance to NNRTIs. Between 10% and 15% of patients in much of sub-Saharan Africa are infected by a strain of HIV resistant to these drugs. If a patient is infected with an NNRTI-resistant strain, they are at a two- to three-fold increased risk of the drug regimen failing.

In 2019, the World Health Organization began to recommend dolutegravir as the preferred first-line treatment for HIV in most populations. Dolutegravir was dubbed a 'wonder drug' because it was safe, potent and cost-effective and scientists had seen no drug resistance against it in clinical trials. However, there is little data on the success of dolutegravir against circulating strains of HIV in sub-Saharan Africa.

In a study published today in Nature Communications, an international team of researchers from South Africa, the UK and the USA examined the genetic code of HIV to determine if drug resistance mutations in 874 volunteers living with HIV affected their treatment success. The individuals were enrolled in a clinical trial for people initiating HIV treatment to compare two drug regimens: efavirenz, an NNRTI and prior first-line therapy in the region, and dolutegravir.

The goal of this study was to determine whether drug resistance to efavirenz prior to starting treatment affected treatment success (suppression of the virus in the blood) over the first two years of therapy with both of these two regimens.

advertisement

As expected, the presence of drug resistance substantially reduced the chances of treatment success in people taking efavirenz, successfully suppressing the virus over 96-weeks in 65% of participants compared to 85% of non-resistant individuals. However, unexpectedly, the same pattern was true for individuals taking dolutegravir-based treatments: 66% of those with efavirenz resistance mutations remained suppressed over 96-weeeks compared to 84% of those without the mutations. These relationships held true after accounting for other factors, such as treatment adherence.

"We fully expected efavirenz to be less effective among patients HIV strains resistant to NNRTIs," said Dr Mark Siedner, faculty member at the Africa Health Research Institute in KwaZulu-Natal, South Africa and Massachusetts General Hospital in Boston, Massachusetts. "What took us completely by surprise was that dolutegravir -- a different class of drug which is generally effective in the face of drug resistance -- would also be less effective in people with these resistant strains.

"We are working now to tease out if this was due to the virus or the participants -- for instance, if people with resistance are less likely to take their pills regularly. Either way, if this pattern holds true, it could have far reaching impacts on our predictions of long-term treatment control for millions of people taking dolutegravir in the region."

Professor Ravi Gupta from the Department of Medicine at the University of Cambridge said: "This a huge concern. Dolutegravir was very much seen as a 'wonder drug', but our study suggests it might not be as effective in a significant number of patients who are resistant to another important class of antiretroviral drugs."

The researchers say it is not clear why efavirenz-resistant mutations should affect susceptibility of dolutegravir, though one hypothesis is that integrase inhibitors such as dolutegravir push the virus to replicate and mutate faster, in turn developing resistance to the new drug in an evolutionary arms race. Alternatively, it could be due to poor adherence to treatment regimens, even though the analysis accounted for adherence by two independent methods. Further research is needed to find out why.

Professor Gupta added: "What this shows is that we urgently need to prioritise point of care tests to identify people with drug resistance HIV, particularly against efavirenz, and to more closely and accurately monitor treatment adherence. The development of such tests is at an advanced stage, but there a lack of investment from funders and philanthropic donors. We urgently need agencies and individuals to step forward and help support these programmes.

"In addition, we need to provide widespread access to viral load monitoring so that we can find those who are struggling, get them on more appropriate regimens, and limit the emergence of resistance when patients are failing therapy."

make a difference: sponsored opportunity

Story Source:

Materials provided by University of Cambridge. The original story is licensed under a Creative Commons License. Note: Content may be edited for style and length.


Journal Reference:

  1. Siedner, MJ et al. Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nature Communications, 2020 DOI: 10.1038/s41467-020-19801-x

Cite This Page:

  • MLA
  • APA
  • Chicago
University of Cambridge. "Warning signs over effectiveness of HIV 'wonder drug' in sub-Saharan Africa." ScienceDaily. ScienceDaily, 1 December 2020. <www.sciencedaily.com/releases/2020/12/201201084802.htm>.
University of Cambridge. (2020, December 1). Warning signs over effectiveness of HIV 'wonder drug' in sub-Saharan Africa. ScienceDaily. Retrieved December 1, 2020 from www.sciencedaily.com/releases/2020/12/201201084802.htm
University of Cambridge. "Warning signs over effectiveness of HIV 'wonder drug' in sub-Saharan Africa." ScienceDaily. www.sciencedaily.com/releases/2020/12/201201084802.htm (accessed December 1, 2020).

  • RELATED TOPICS
    • Health & Medicine
      • HIV and AIDS
      • Pharmacology
      • Infectious Diseases
      • Pharmaceuticals
    • Plants & Animals
      • Virology
      • Biotechnology
      • Bacteria
      • Microbes and More
advertisement

  • RELATED TERMS
    • Antiretroviral drug
    • Drug addiction
    • AIDS
    • HIV test
    • Pharmaceutical company
    • Clinical trial
    • Breast cancer
    • Stem cell treatments

1

2

3

4

5
RELATED STORIES

New Strains of Hepatitis C Found in Africa
Dec. 17, 2018 — The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa. The discovery suggests certain antiviral ...
New HIV Therapy Reduces Virus, Boosts Immunity in Drug-Resistant Patients
Aug. 15, 2018 — A new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a ...
HIV: A Therapeutic Advance for Resource-Limited Settings
May 29, 2017 — A clinical trial running in parallel in three countries in sub-Saharan Africa, shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in ...
Novel Pharmaceutic Action for HIV/AIDS Discovered
Feb. 1, 2017 — Using a process called LASER ART (long-acting slow effective release antiretroviral therapy), a research team has discovered an unexpected pathway to open cell storage areas for antiviral drugs. The ...
FROM AROUND THE WEB

ScienceDaily shares links with sites in the TrendMD network and earns revenue from third-party advertisers, where indicated.
  Print   Email   Share

advertisement

1

2

3

4

5
Most Popular
this week

HEALTH & MEDICINE
Hyperbaric Oxygen Treatment: Clinical Trial Reverses Two Biological Processes Associated With Aging in Human Cells
The Six Strains of SARS-CoV-2
Researchers Examine Which Approaches Are Most Effective at Reducing COVID-19 Spread
MIND & BRAIN
Zebra Finches Amazing at Unmasking the Bird Behind the Song
From the Inside Out: How the Brain Forms Sensory Memories
Healthy Sleep Habits Help Lower Risk of Heart Failure
LIVING & WELL
Boy or Girl? It's in the Father's Genes
Cocoa Flavanols Boost Brain Oxygenation, Cognition in Healthy Adults
Hormone Found to Switch Off Hunger Could Help Tackle Obesity
advertisement

Strange & Offbeat
 

HEALTH & MEDICINE
Biofriendly Protocells Pump Up Blood Vessels
Researchers Identify Features That Could Make Someone a Virus Super-Spreader
New Effective and Safe Antifungal Isolated from Sea Squirt Microbiome
MIND & BRAIN
Zebra Finches Amazing at Unmasking the Bird Behind the Song
A Malformation Illustrates the Incredible Plasticity of the Brain
Water Fleas on 'Happy Pills' Have More Offspring
LIVING & WELL
Key Advance for Printing Circuitry on Wearable Fabrics
Luminescent Wood Could Light Up Homes of the Future
Research Lays Groundwork for Ultra-Thin, Energy Efficient Photodetector on Glass
SD
  • SD
    • Home Page
    • Top Science News
    • Latest News
  • Home
    • Home Page
    • Top Science News
    • Latest News
  • Health
    • View all the latest top news in the health sciences,
      or browse the topics below:
      Health & Medicine
      • Allergy
      • Alternative Medicine
      • Birth Control
      • Cancer
      • Diabetes
      • Diseases
      • Heart Disease
      • HIV and AIDS
      • Obesity
      • Stem Cells
      • ... more topics
      Mind & Brain
      • ADD and ADHD
      • Addiction
      • Alzheimer's
      • Autism
      • Depression
      • Headaches
      • Intelligence
      • Psychology
      • Relationships
      • Schizophrenia
      • ... more topics
      Living Well
      • Parenting
      • Pregnancy
      • Sexual Health
      • Skin Care
      • Men's Health
      • Women's Health
      • Nutrition
      • Diet and Weight Loss
      • Fitness
      • Healthy Aging
      • ... more topics
  • Tech
    • View all the latest top news in the physical sciences & technology,
      or browse the topics below:
      Matter & Energy
      • Aviation
      • Chemistry
      • Electronics
      • Fossil Fuels
      • Nanotechnology
      • Physics
      • Quantum Physics
      • Solar Energy
      • Technology
      • Wind Energy
      • ... more topics
      Space & Time
      • Astronomy
      • Black Holes
      • Dark Matter
      • Extrasolar Planets
      • Mars
      • Moon
      • Solar System
      • Space Telescopes
      • Stars
      • Sun
      • ... more topics
      Computers & Math
      • Artificial Intelligence
      • Communications
      • Computer Science
      • Hacking
      • Mathematics
      • Quantum Computers
      • Robotics
      • Software
      • Video Games
      • Virtual Reality
      • ... more topics
  • Enviro
    • View all the latest top news in the environmental sciences,
      or browse the topics below:
      Plants & Animals
      • Agriculture and Food
      • Animals
      • Biology
      • Biotechnology
      • Endangered Animals
      • Extinction
      • Genetically Modified
      • Microbes and More
      • New Species
      • Zoology
      • ... more topics
      Earth & Climate
      • Climate
      • Earthquakes
      • Environment
      • Geography
      • Geology
      • Global Warming
      • Hurricanes
      • Ozone Holes
      • Pollution
      • Weather
      • ... more topics
      Fossils & Ruins
      • Ancient Civilizations
      • Anthropology
      • Archaeology
      • Dinosaurs
      • Early Humans
      • Early Mammals
      • Evolution
      • Lost Treasures
      • Origin of Life
      • Paleontology
      • ... more topics
  • Society
    • View all the latest top news in the social sciences & education,
      or browse the topics below:
      Science & Society
      • Arts & Culture
      • Consumerism
      • Economics
      • Political Science
      • Privacy Issues
      • Public Health
      • Racial Disparity
      • Religion
      • Sports
      • World Development
      • ... more topics
      Business & Industry
      • Biotechnology & Bioengineering
      • Computers & Internet
      • Energy & Resources
      • Engineering
      • Medical Technology
      • Pharmaceuticals
      • Transportation
      • ... more topics
      Education & Learning
      • Animal Learning & Intelligence
      • Creativity
      • Educational Psychology
      • Educational Technology
      • Infant & Preschool Learning
      • Learning Disorders
      • STEM Education
      • ... more topics
  • Quirky
    • Top News
    • Human Quirks
    • Odd Creatures
    • Bizarre Things
    • Weird World
Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

  • Email Newsletters
  • RSS Feeds
Follow Us

Keep up to date with the latest news from ScienceDaily via social networks:

  • Facebook
  • Twitter
  • LinkedIn
Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

  • Leave Feedback
  • Contact Us
About This Site  |  Staff  |  Reviews  |  Contribute  |  Advertise  |  Privacy Policy  |  Editorial Policy  |  Terms of Use
Copyright 2020 ScienceDaily or by other parties, where indicated. All rights controlled by their respective owners.
Content on this website is for information only. It is not intended to provide medical or other professional advice.
Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners.
Financial support for ScienceDaily comes from advertisements and referral programs, where indicated.
— CCPA: Do Not Sell My Information — — GDPR: Privacy Settings —